NO981592D0 - Anvendelse av <gamma>-RAR-spesifikk agonistligand for Õ ÷ke apoptosisraten - Google Patents

Anvendelse av <gamma>-RAR-spesifikk agonistligand for Õ ÷ke apoptosisraten

Info

Publication number
NO981592D0
NO981592D0 NO981592A NO981592A NO981592D0 NO 981592 D0 NO981592 D0 NO 981592D0 NO 981592 A NO981592 A NO 981592A NO 981592 A NO981592 A NO 981592A NO 981592 D0 NO981592 D0 NO 981592D0
Authority
NO
Norway
Prior art keywords
rar
gamma
apoptosis rate
specific agonist
agonist ligand
Prior art date
Application number
NO981592A
Other languages
English (en)
Other versions
NO981592L (no
Inventor
Laszlo Fesus
Zsuzsa Szondy
Uwe Reichert
Original Assignee
Cird Galderma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cird Galderma filed Critical Cird Galderma
Publication of NO981592D0 publication Critical patent/NO981592D0/no
Publication of NO981592L publication Critical patent/NO981592L/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
NO981592A 1995-10-09 1998-04-07 Anvendelse av <gamma>-RAR-spesifikk agonistligand for Õ °ke apoptosisraten NO981592L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9512179A FR2739557B1 (fr) 1995-10-09 1995-10-09 Utilisation d'un ligand agoniste specifique rar-gamma
PCT/FR1996/001568 WO1997013505A2 (fr) 1995-10-09 1996-10-08 UTILISATION D'UN LIGAND AGONISTE SPECIFIQUE RAR-η POUR AUGMENTER LE TAUX D'APOPTOSE

Publications (2)

Publication Number Publication Date
NO981592D0 true NO981592D0 (no) 1998-04-07
NO981592L NO981592L (no) 1998-06-09

Family

ID=9483613

Family Applications (1)

Application Number Title Priority Date Filing Date
NO981592A NO981592L (no) 1995-10-09 1998-04-07 Anvendelse av <gamma>-RAR-spesifikk agonistligand for Õ °ke apoptosisraten

Country Status (16)

Country Link
US (4) US6593359B1 (no)
EP (1) EP0854710A2 (no)
JP (1) JP3135266B2 (no)
KR (1) KR19990064139A (no)
CN (1) CN1121857C (no)
AU (1) AU705993B2 (no)
BR (1) BR9610967A (no)
CA (1) CA2231561A1 (no)
FR (1) FR2739557B1 (no)
HU (1) HUP9900453A3 (no)
NO (1) NO981592L (no)
NZ (1) NZ319646A (no)
PL (1) PL185826B1 (no)
RU (1) RU2188037C2 (no)
TR (1) TR199800645T1 (no)
WO (1) WO1997013505A2 (no)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070213290A1 (en) * 1996-10-17 2007-09-13 Kingsman Alan J Neurite regeneration
US20040266715A1 (en) * 1999-03-31 2004-12-30 Wong Liang Fong Neurite regeneration
US20030053991A1 (en) * 2000-10-04 2003-03-20 Kingsman Alan John Retinoic acid receptor beta-2, its agonists, and gene theraphy vectors for the treatment of neurological disorders
GB9907461D0 (en) * 1999-03-31 1999-05-26 King S College London Neurite regeneration
FR2757852B1 (fr) 1996-12-31 1999-02-19 Cird Galderma Composes stilbeniques a groupement adamantyl, compositions les contenant et utilisations
WO1999024024A2 (en) 1997-11-12 1999-05-20 F. Hoffmann-La Roche Ag Treatment of t-helper cell type 2 mediated immune diseases with retinoid antagonists
US6083973A (en) * 1998-03-09 2000-07-04 Syntex (U.S.A.) Inc. Methods for inhibiting mucin secretion using RAR α selective antagonists
US6949528B1 (en) * 1998-03-18 2005-09-27 Goddard John G Compositions containing lysophosphatidic acids which inhibit apoptosis and uses thereof
JO2178B1 (en) * 1999-10-19 2003-04-23 اف . هوفمان لاروش ايه جي Treatment of invasive diseases, using selected anti-PAR materials
WO2004050101A2 (en) * 2002-11-29 2004-06-17 Gpc Biotech Ag Formulations useful against hepatitis c virus infections
US20050202055A1 (en) * 2004-03-11 2005-09-15 Koichi Shudo, Tokyo, Japan Anti-wrinkle agent
EP1727516B1 (en) * 2004-03-26 2014-05-14 DSM IP Assets B.V. Composition comprising an hdac inhibitor in combination with a retinoid
US7713266B2 (en) * 2005-05-20 2010-05-11 Myoscience, Inc. Subdermal cryogenic remodeling of muscles, nerves, connective tissue, and/or adipose tissue (fat)
US7850683B2 (en) * 2005-05-20 2010-12-14 Myoscience, Inc. Subdermal cryogenic remodeling of muscles, nerves, connective tissue, and/or adipose tissue (fat)
US9254162B2 (en) * 2006-12-21 2016-02-09 Myoscience, Inc. Dermal and transdermal cryogenic microprobe systems
US8409185B2 (en) 2007-02-16 2013-04-02 Myoscience, Inc. Replaceable and/or easily removable needle systems for dermal and transdermal cryogenic remodeling
US8298216B2 (en) 2007-11-14 2012-10-30 Myoscience, Inc. Pain management using cryogenic remodeling
WO2010075438A1 (en) 2008-12-22 2010-07-01 Myoscience, Inc. Integrated cryosurgical system with refrigerant and electrical power source
EP2613776B1 (en) * 2010-09-01 2020-07-29 Thomas Jefferson University Composition and method for muscle repair and regeneration
CN103732231B (zh) * 2011-06-24 2020-04-10 格里生物公司 炎性病症的预防和治疗
EP2802278B1 (en) 2012-01-13 2016-12-07 Myoscience, Inc. Cryogenic probe filtration system
BR112014017175A8 (pt) 2012-01-13 2017-07-04 Myoscience Inc proteção de pele para remodelagem criogênica subdérmica para tratamentos cosméticos e outros
US9314290B2 (en) 2012-01-13 2016-04-19 Myoscience, Inc. Cryogenic needle with freeze zone regulation
US9017318B2 (en) 2012-01-20 2015-04-28 Myoscience, Inc. Cryogenic probe system and method
US20140350536A1 (en) 2013-03-15 2014-11-27 Myoscience, Inc. Cryogenic Blunt Dissection Methods and Devices
WO2014146122A1 (en) 2013-03-15 2014-09-18 Myoscience, Inc. Methods and systems for treatment of occipital neuralgia
US9295512B2 (en) 2013-03-15 2016-03-29 Myoscience, Inc. Methods and devices for pain management
US9610112B2 (en) 2013-03-15 2017-04-04 Myoscience, Inc. Cryogenic enhancement of joint function, alleviation of joint stiffness and/or alleviation of pain associated with osteoarthritis
US10130409B2 (en) 2013-11-05 2018-11-20 Myoscience, Inc. Secure cryosurgical treatment system
EP4098257A1 (en) 2015-11-25 2022-12-07 IO Therapeutics, Inc. Use of cyp26-resistant rar alpha selective agonists in the treatment of cancer
US11311327B2 (en) 2016-05-13 2022-04-26 Pacira Cryotech, Inc. Methods and systems for locating and treating nerves with cold therapy
CN115671292A (zh) 2016-06-10 2023-02-03 Io治疗公司 用于癌症免疫疗法的受体选择性类视黄醇和rexinoid化合物和免疫调节剂
IL302133A (en) 2017-07-13 2023-06-01 Io Therapeutics Inc A combination of a rexinoid and retinoid substance with immunomodulatory properties and immunomodulatory substances for cancer treatment
AU2018326617B2 (en) 2017-08-31 2022-12-01 Io Therapeutics, Inc. Rar selective agonists in combination with immune modulators for cancer immunotherapy
US11134998B2 (en) 2017-11-15 2021-10-05 Pacira Cryotech, Inc. Integrated cold therapy and electrical stimulation systems for locating and treating nerves and associated methods
US11135236B2 (en) * 2018-04-10 2021-10-05 Northwestern University Retinoic acid receptor gamma agonists to attenuate anthracycline-induced cardiotoxicity

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5786391A (en) * 1995-01-11 1998-07-28 Cornell Research Foundation, Inc. Regulating gene expression using retinoids with Ch2 OH or related groups at the side chain terminal position
EP0850067A4 (en) * 1995-07-17 1999-12-15 Cird Galderma METHOD FOR CANCER TREATMENT USING 6- (3- (1-ADAMANTYL) -4-HYDROXYPHENYL) 2 NAPHTALINE CARBONIC ACID

Also Published As

Publication number Publication date
NZ319646A (en) 2000-08-25
NO981592L (no) 1998-06-09
US20010018456A1 (en) 2001-08-30
HUP9900453A2 (hu) 1999-05-28
EP0854710A2 (fr) 1998-07-29
PL185826B1 (pl) 2003-08-29
CN1203528A (zh) 1998-12-30
AU705993B2 (en) 1999-06-03
CA2231561A1 (fr) 1997-04-17
US6506796B1 (en) 2003-01-14
AU7220996A (en) 1997-04-30
JPH11501661A (ja) 1999-02-09
WO1997013505A3 (fr) 1997-05-29
CN1121857C (zh) 2003-09-24
KR19990064139A (ko) 1999-07-26
FR2739557B1 (fr) 1997-11-14
RU2188037C2 (ru) 2002-08-27
US6686386B1 (en) 2004-02-03
JP3135266B2 (ja) 2001-02-13
PL326077A1 (en) 1998-08-17
FR2739557A1 (fr) 1997-04-11
US6593359B1 (en) 2003-07-15
WO1997013505A2 (fr) 1997-04-17
HUP9900453A3 (en) 1999-11-29
BR9610967A (pt) 1999-03-02
TR199800645T1 (xx) 1998-06-22

Similar Documents

Publication Publication Date Title
NO981592D0 (no) Anvendelse av &lt;gamma&gt;-RAR-spesifikk agonistligand for Õ ÷ke apoptosisraten
DK0981336T3 (da) Anvendelse af peroxygenforbindelser til bekæmpelse af digital dermatitis
DK0679400T3 (da) Orale doseringsformer af azithromycin til undgåelse af lægemiddelfødevareinteraktion
NO975494L (no) Stabiliserte fluider inneholdende oppl÷selig sink
HUP9900037A3 (en) Use of rar-gamma antagonist or alfa-rar-alfa agonist ligands to prepare pharmaceutical compositions for reducing apoptosis
NO932585L (no) Katalytisk reaktorlag
NO20010899L (no) Forbedring av ugunstige apomorfin-effekter
NO932388L (no) Fremgangsmaater til fraktur-syrebehandling av undervannsformasjoner
NO933087L (no) Flytende s}pe for personlig hygiene
NO921402L (no) Tankagitator for tidlig hydratisering av konsentrert, flytende, geledannende middel
NO980522L (no) En-sats syntese av 2-oksazolidinonderivater
NO983298L (no) System for Õ begrense bruk av et mÕleapparat
DE69819903D1 (de) Bizyklische verbindungen als liganden der 5-ht1 rezeptoren
NO934066D0 (no) Middel til hindring av polymeravleiring
KR870700515A (ko) 내마모성 닥터 브레이드
PL319440A1 (en) Analoques of antiviral nuceosides containing substituted benzimidazoles attached to the carbocyclic ring
DK89697A (da) Anvendelse af melatonin til behandling af patienter, der lider af medikamentafhængighed
IT1148169B (it) Composti carcinostatici e procedimento per la loro sintesi
DK440582A (da) Middel til fremme af mundhygiejnen
NO940190L (no) Anvendelse av alpha-ketoglutarat
NO934855D0 (no) Middel til aa hindre dannelse av polymerflak
NO931713D0 (no) Maaling av flerfase-fluidumstroemning
DE69507254D1 (de) Bizyklische Verbindungen zur Hemmung der Plättchenaggregation
NO942310D0 (no) Middel for undertrykkelse av infiltrering av eosinofiler
MX174575B (es) Recuperacion de cantidades de acetilo desde diacetato de etilideno

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application